All News about Bluebird Bio
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
Via MarketBeat
Topics
Artificial Intelligence
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
Via Benzinga
Exposures
Product Safety
2 Red Flags for Bluebird Bio Stock
January 10, 2024
Via The Motley Fool
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 21, 2023
Via Benzinga
S&P 500 Edges Lower; General Mills Cuts Sales Forecast
December 20, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 20, 2023
Via Benzinga
Crude Oil Rises 1%; US Current Account Gap Narrows In Q3
December 20, 2023
Via Benzinga
Topics
Stocks
US Stocks Mostly Lower; FedEx Earnings Miss Estimates
December 20, 2023
Via Benzinga
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
December 20, 2023
Via Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 20, 2023
Via Benzinga
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
December 19, 2023
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 19, 2023
Via Benzinga
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
December 19, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.